Synbiotic takes over GECA Pharma

The cannabinoid start-up is thus adding the next company to its group of companies. Synbiotic is now also entering the medical cannabis market.

The cannabinoid company Synbiotic is acquiring 100 percent of Cologne-based GECA Pharma GmbH. The Cologne-based company is to take over the pharmaceutical arm of the listed start-up in future. "We are one of the first German listed cannabis companies to open up the market for medicinal cannabis," says Synbiotic CEO Lars Müller.

Müller assumes that the market for medical cannabis in the EU alone will be worth several billion euros. Synbiotic CEO Lars Müller spoke to Startbase back in February about his big plans. The cannabinoid start-up aims to become the leading provider in Europe. To this end, Synbiotic wants to take over more and more companies in order to expand its position. In March, for example, Synbiotic acquired a stake in Stuttgart-based start-up The Hempany. In April, it secured shares in the Canadian cannabinoid company NeuroTheryX.

According to Synbiotic, GECA Pharma is already profitable and generates almost 900,000 euros in revenue from the trade in medicinal cannabis flowers alone.